See more : PT Archi Indonesia Tbk (ARCI.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Surgalign Holdings, Inc. (SRGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Surgalign Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Gilead Sciences, Inc. (GILD.SW) Income Statement Analysis – Financial Results
- Intertainment AG (ITN.DE) Income Statement Analysis – Financial Results
- CYND Co., Ltd. (4256.T) Income Statement Analysis – Financial Results
- Norwegian Air Shuttle ASA (NWARF) Income Statement Analysis – Financial Results
- Qtone Education Group (Guangdong) Co.,Ltd (300359.SZ) Income Statement Analysis – Financial Results
Surgalign Holdings, Inc. (SRGA)
About Surgalign Holdings, Inc.
Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.98M | 90.50M | 101.75M | 117.42M | 280.86M | 279.56M | 272.87M | 282.29M | 262.81M | 197.98M | 178.11M | 169.32M | 166.17M | 164.53M | 146.64M | 94.21M | 73.97M | 75.20M | 92.70M | 75.51M | 118.49M | 140.73M | 122.50M | 33.03M |
| Cost of Revenue | 41.69M | 29.78M | 44.00M | 32.78M | 140.73M | 137.04M | 140.52M | 132.55M | 129.01M | 117.87M | 92.90M | 92.10M | 90.17M | 87.03M | 77.82M | 56.56M | 54.65M | 55.46M | 55.53M | 42.77M | 94.31M | 112.63M | 91.28M | 18.60M |
| Gross Profit | 40.29M | 60.73M | 57.75M | 84.65M | 140.12M | 142.52M | 132.35M | 149.74M | 133.80M | 80.11M | 85.22M | 77.21M | 76.00M | 77.49M | 68.81M | 37.65M | 19.32M | 19.74M | 37.18M | 32.74M | 24.18M | 28.10M | 31.22M | 14.43M |
| Gross Profit Ratio | 49.14% | 67.10% | 56.75% | 72.09% | 49.89% | 50.98% | 48.50% | 53.04% | 50.91% | 40.46% | 47.84% | 45.60% | 45.74% | 47.10% | 46.93% | 39.97% | 26.12% | 26.25% | 40.10% | 43.36% | 20.41% | 19.96% | 25.49% | 43.69% |
| Research & Development | 15.74M | 13.89M | 11.95M | 16.84M | 14.41M | 13.38M | 16.09M | 15.07M | 15.54M | 15.24M | 12.23M | 9.81M | 9.44M | 8.90M | 8.14M | 5.19M | 5.40M | 5.00M | 3.84M | 2.44M | 2.46M | 2.63M | 2.39M | 1.68M |
| General & Administrative | 95.89M | 104.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.80M | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 119.22M | 115.10M | 116.13M | 107.44M | 107.65M | 81.64M | 58.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 95.89M | 104.67M | 124.39M | 135.40M | 119.22M | 115.10M | 116.13M | 107.44M | 112.45M | 81.64M | 58.40M | 55.64M | 59.23M | 59.33M | 54.17M | 31.04M | 27.25M | 23.35M | 23.22M | 23.52M | 29.24M | 35.96M | 20.58M | 9.74M |
| Other Expenses | -898.00K | -3.93M | 75.43M | 41.21M | 0.00 | 0.00 | 3.83M | 0.00 | -4.80M | 0.00 | -20.00K | 0.00 | 0.00 | 0.00 | 104.41M | 4.19M | 4.20M | 336.00K | 136.00K | 169.00K | 5.10M | 0.00 | 1.45M | 576.09K |
| Operating Expenses | 110.73M | 114.62M | 136.34M | 152.23M | 133.63M | 128.48M | 136.05M | 122.50M | 123.19M | 96.88M | 70.61M | 65.44M | 68.67M | 68.22M | 166.72M | 40.42M | 36.86M | 28.69M | 27.20M | 26.13M | 36.79M | 38.59M | 24.42M | 11.99M |
| Cost & Expenses | 152.42M | 144.40M | 180.34M | 185.01M | 274.36M | 265.52M | 276.56M | 255.06M | 252.20M | 214.75M | 163.50M | 157.55M | 158.84M | 155.26M | 244.54M | 96.97M | 91.50M | 84.15M | 82.72M | 68.89M | 131.10M | 151.22M | 115.70M | 30.59M |
| Interest Income | 0.00 | 0.00 | 92.00K | 161.00K | 35.00K | 8.00K | 8.00K | 3.00K | 9.00K | 23.00K | 185.00K | 193.00K | 114.00K | 273.00K | 567.00K | 849.00K | 934.00K | 361.00K | 96.00K | 235.00K | 186.00K | 1.31M | 1.21M | 0.00 |
| Interest Expense | 1.01M | 0.00 | 31.00K | 12.57M | 2.77M | 3.18M | 1.66M | 1.49M | 1.36M | 542.00K | 0.00 | 201.00K | 537.00K | 544.00K | 797.00K | 753.00K | 898.00K | 862.00K | 967.00K | 981.00K | 2.76M | 106.00K | 434.00K | 0.00 |
| Depreciation & Amortization | 2.16M | 2.48M | 6.67M | 22.68M | 14.57M | 14.23M | 16.51M | 16.52M | 15.40M | 12.20M | 7.99M | 8.03M | 7.50M | 7.14M | 6.16M | 5.42M | 5.33M | 4.33M | 4.06M | 4.41M | 2.89M | 2.34M | 1.45M | 576.09K |
| EBITDA | -68.28M | -3.93M | -71.92M | -181.86M | 11.76M | 43.13M | 705.00K | 41.23M | 20.94M | -16.18M | 20.44M | 19.83M | -119.76M | 16.14M | -91.63M | 3.70M | -11.27M | -4.26M | 14.13M | 11.27M | -10.89M | -124.24M | 9.46M | 2.92M |
| EBITDA Ratio | -83.29% | 20.64% | -70.68% | 111.15% | 4.19% | 15.43% | 0.26% | 14.60% | 7.97% | -8.17% | 11.47% | 11.71% | -72.07% | 9.81% | -62.49% | 3.93% | -15.23% | -5.66% | 15.24% | 14.92% | -9.19% | -4.86% | 7.72% | 8.83% |
| Operating Income | -70.44M | 16.20M | -78.59M | 107.85M | -2.50M | 28.81M | -15.68M | 24.63M | 5.63M | -28.66M | 12.24M | 11.77M | -127.38M | 9.02M | -98.36M | -2.57M | -17.53M | -8.95M | 9.98M | 6.62M | -13.97M | -10.50M | 6.80M | 2.44M |
| Operating Income Ratio | -85.92% | 17.90% | -77.24% | 91.84% | -0.89% | 10.31% | -5.75% | 8.72% | 2.14% | -14.47% | 6.87% | 6.95% | -76.65% | 5.48% | -67.08% | -2.73% | -23.70% | -11.90% | 10.76% | 8.77% | -11.79% | -7.46% | 5.55% | 7.38% |
| Total Other Income/Expenses | 14.79M | -119.86M | -119.09M | -61.00M | -1.27M | -3.09M | -1.78M | -1.41M | -1.44M | -268.00K | 204.00K | -167.00K | -419.00K | -564.00K | -230.00K | 96.00K | 36.00K | -501.00K | -871.00K | -746.00K | -2.57M | 1.21M | 774.00K | -98.15K |
| Income Before Tax | -55.65M | -123.79M | -197.68M | -242.86M | -5.58M | 25.73M | -17.46M | 23.21M | 4.19M | -28.92M | 12.44M | 11.60M | -127.79M | 8.46M | -98.59M | -2.47M | -17.50M | -9.45M | 9.11M | 5.87M | -16.54M | -9.29M | 7.58M | 2.34M |
| Income Before Tax Ratio | -67.88% | -136.79% | -194.28% | -206.82% | -1.99% | 9.20% | -6.40% | 8.22% | 1.59% | -14.61% | 6.99% | 6.85% | -76.91% | 5.14% | -67.23% | -2.62% | -23.66% | -12.56% | 9.82% | 7.78% | -13.96% | -6.60% | 6.18% | 7.09% |
| Income Tax Expense | -1.04M | -886.00K | -3.49M | 5.92M | -4.33M | 19.45M | -3.06M | 8.30M | 1.49M | -11.11M | 4.04M | 3.23M | 1.61M | 2.60M | 1.39M | -376.00K | -6.37M | -3.90M | 2.95M | -483.00K | -3.03M | -3.79M | 3.12M | -618.86K |
| Net Income | -54.61M | -122.91M | -194.20M | -248.78M | -1.25M | 6.27M | -14.40M | 14.92M | 2.70M | -17.81M | 8.40M | 8.38M | -129.40M | 5.86M | -99.98M | -2.10M | -11.13M | -5.55M | 6.16M | 6.36M | -13.51M | -5.51M | 4.46M | 2.96M |
| Net Income Ratio | -66.61% | -135.81% | -190.86% | -211.86% | -0.45% | 2.24% | -5.28% | 5.28% | 1.03% | -9.00% | 4.72% | 4.95% | -77.87% | 3.56% | -68.18% | -2.22% | -15.04% | -7.38% | 6.64% | 8.42% | -11.40% | -3.91% | 3.64% | 8.96% |
| EPS | -8.33 | -30.08 | -78.30 | -106.39 | -0.02 | 0.11 | -0.25 | 0.26 | 0.05 | -0.32 | 0.15 | 0.15 | -2.36 | 0.11 | -2.00 | -0.07 | -0.37 | -0.20 | 0.23 | 0.24 | -0.60 | -0.25 | 0.42 | 0.81 |
| EPS Diluted | -8.33 | -30.08 | -78.30 | -106.39 | -0.02 | 0.10 | -0.25 | 0.25 | 0.05 | -0.32 | 0.15 | 0.15 | -2.36 | 0.11 | -2.00 | -0.07 | -0.37 | -0.20 | 0.23 | 0.24 | -0.60 | -0.25 | 0.22 | 0.18 |
| Weighted Avg Shares Out | 6.56M | 4.09M | 2.48M | 2.34M | 63.52M | 59.68M | 58.24M | 57.61M | 56.74M | 56.26M | 55.86M | 55.15M | 54.73M | 54.35M | 49.91M | 29.82M | 29.75M | 27.75M | 26.59M | 26.37M | 22.43M | 21.76M | 10.64M | 3.67M |
| Weighted Avg Shares Out (Dil) | 6.56M | 4.09M | 2.48M | 2.34M | 63.52M | 60.60M | 58.24M | 58.59M | 56.74M | 56.26M | 56.07M | 55.35M | 54.73M | 54.77M | 49.91M | 29.82M | 29.75M | 27.75M | 27.06M | 27.00M | 22.43M | 21.76M | 20.34M | 16.64M |
Surgalign Holdings and Aziyo Biologics Announce Expanded Distribution Agreement
Surgalign Holdings, Inc. Schedules Third Quarter 2020 Earnings Release for November 11, 2020
Surgalign Holdings, Inc. Announces Date Change for Third Quarter 2020 Earnings Release and Conference Call
Surgalign Holdings, Inc. Schedules Third Quarter 2020 Earnings Call for November 6 and Virtual Investor Day for November 12, 2020
Source: https://incomestatements.info
Category: Stock Reports